Edition:
India

Kitov Pharmaceuticals Holdings Ltd (KTOV.OQ)

KTOV.OQ on NASDAQ Stock Exchange Capital Market

2.33USD
22 Nov 2017
Change (% chg)

$0.15 (+6.88%)
Prev Close
$2.18
Open
$2.10
Day's High
$2.39
Day's Low
$2.10
Volume
156,542
Avg. Vol
81,887
52-wk High
$3.73
52-wk Low
$1.27

Select another date:

Wed, Nov 1 2017

BRIEF-Kitov pharmaceuticals announces receipt of FDA's favorable response to NT219's pre-ind meeting package

* Kitov Pharmaceuticals announces receipt of FDA's favorable response to NT219's pre-ind meeting package

BRIEF-Kitov Pharmaceuticals announces phase III/IV clinical trial for KIT-302 successfully meets primary endpoint

* Kitov pharmaceuticals announces phase iii/iv clinical trial for kit-302 successfully meets primary endpoint, and also demonstrates drug candidate improves renal function

BRIEF-Kitov boosts ownership in Tyrnovo and Oncology platform

* Kitov boosts ownership in Tyrnovo and Oncology platform through exchange of shares for stock

BRIEF-Kitov posts filing by FDA of New Drug Application for KIT-302

* Kitov announces filing by FDA of New Drug Application for KIT-302

BRIEF-Kitov submits new drug application to FDA for KIT-302

* Says ‍company expects that within 60 days FDA will determine whether NDA is complete and acceptable for filing​

BRIEF-Kitov announces results of study demonstrating NT-219 enhanced efficacy of keytruda in immune-oncology preclinical model

* Kitov announces results of study demonstrating NT-219 enhanced efficacy of keytruda in immune-oncology preclinical model

BRIEF-Kitov Pharma enters agreements with investors

* Kitov Pharmaceuticals - entered agreements with investors providing for issuance of 2.4 million ads at purchase price of $1.45 per ADS - SEC filing‍​

Select another date: